Literature DB >> 7640156

Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.

C L Szumlanski1, R M Weinshilboum.   

Abstract

Thiopurine drugs are used in the treatment of inflammatory bowel disease--as are sulphasalazine and its metabolite 5-aminosalicylic acid (ASA). S-Methylation catalyzed by thiopurine methyltransferase (TPMT) is a major pathway in the metabolism of thiopurines. The hypothesis was tested that TPMT might be inhibited by sulphasalazine or isomers of ASA. Sulphasalazine as well as 3-, 4- and 5-ASA inhibited recombinant human TPMT, with IC50 values of 78, 99, 2600 and 1240 microM, respectively. Kinetic studies demonstrated that the inhibition of TPMT by sulphasalazine and ASA isomers was non-competitive with regard to the thiopurine substrate, 6-MP, and was uncompetitive with regard to the methyl donor for the reaction, S-adenosyl-L-methionine. Our observations raise the possibility of a clinically significant drug-drug interaction in patients treated simultaneously with sulphasalazine and thiopurine drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640156      PMCID: PMC1365137          DOI: 10.1111/j.1365-2125.1995.tb04478.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

Review 1.  Methyltransferase pharmacogenetics.

Authors:  R Weinshilboum
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

2.  Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient.

Authors:  E Schütz; J Gummert; F Mohr; M Oellerich
Journal:  Lancet       Date:  1993-02-13       Impact factor: 79.321

3.  Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies.

Authors:  L C Woodson; J H Dunnette; R M Weinshilboum
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

4.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity.

Authors:  D H Present; S J Meltzer; M P Krumholz; A Wolke; B I Korelitz
Journal:  Ann Intern Med       Date:  1989-10-15       Impact factor: 25.391

5.  Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA.

Authors:  R Honchel; I A Aksoy; C Szumlanski; T C Wood; D M Otterness; E D Wieben; R M Weinshilboum
Journal:  Mol Pharmacol       Date:  1993-06       Impact factor: 4.436

6.  Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism.

Authors:  L Lennard; J A Van Loon; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

7.  Human kidney thiopurine methyltransferase. Purification and biochemical properties.

Authors:  L C Woodson; R M Weinshilboum
Journal:  Biochem Pharmacol       Date:  1983-03-01       Impact factor: 5.858

Review 8.  New therapeutic agents in the treatment of inflammatory bowel disease.

Authors:  D L Geier; P B Miner
Journal:  Am J Med       Date:  1992-08       Impact factor: 4.965

9.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.

Authors:  L Lennard; J S Lilleyman; J Van Loon; R M Weinshilboum
Journal:  Lancet       Date:  1990-07-28       Impact factor: 79.321

10.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.

Authors:  W E Evans; M Horner; Y Q Chu; D Kalwinsky; W M Roberts
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

View more
  38 in total

1.  Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.

Authors:  P W Lowry; C L Franklin; A L Weaver; M G Pike; D C Mays; W J Tremaine; J J Lipsky; W J Sandborn
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

2.  Identifying mechanism-of-action targets for drugs and probes.

Authors:  Elisabet Gregori-Puigjané; Vincent Setola; Jérôme Hert; Brenda A Crews; John J Irwin; Eugen Lounkine; Lawrence Marnett; Bryan L Roth; Brian K Shoichet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

3.  Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine.

Authors:  T Dervieux; Y Médard; V Baudouin; A Maisin; D Zhang; F Broly; C Loirat; E Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

4.  Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.

Authors:  Gabriele Stocco; Eva Cuzzoni; Sara De Iudicibus; Diego Favretto; Noelia Malusà; Stefano Martelossi; Elena Pozzi; Paolo Lionetti; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 5.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 6.  Current therapy of pediatric Crohn's disease.

Authors:  Avishay Lahad; Batia Weiss
Journal:  World J Gastrointest Pathophysiol       Date:  2015-05-15

7.  Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

Authors:  P W Lowry; C L Franklin; A L Weaver; C L Szumlanski; D C Mays; E V Loftus; W J Tremaine; J J Lipsky; R M Weinshilboum; W J Sandborn
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

8.  Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies.

Authors:  Fernando Bermejo; Javier P Gisbert
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

9.  Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.

Authors:  Ivanka Curkovic; Katharina M Rentsch; Pascal Frei; Michael Fried; Gerhard Rogler; Gerd A Kullak-Ublick; Alexander Jetter
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

10.  Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Authors:  K Schmiegelow; E Forestier; J Kristinsson; S Söderhäll; K Vettenranta; R Weinshilboum; F Wesenberg
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.